 ZURICH, SWITZERLAND ACCESSWIRE January 11, 2023 NLS Pharmaceutics Ltd. Nasdaq:NLSP, NLSPW NLS or the Company, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, is pleased to announce its participation in the following upcoming conferences: 2023 BIO CEO Investor Conference Alex Zwyer, NLS Chief Executive Officer, will present a company update at the 2023 BIO CEO Investor Conference on March 12-14, 2023, and will be available for one-on-one meetings with conference attendees. 